Welcome to Lundbeck!

Quote



anonymous said:
love how people chime in on here without knowing a single thing. lundbeck has an MS and psych salesforce. No way they can sell 4 MS drugs and a brand new migraine infusion. New sales force will be necessary
Click to expand...

I kinda believe in this post. Lundbeck reps may be good but they wouldn't know much, if anything, about bill to/send to purchasing accounts. They will need experienced account reps with infusion sales experience and B&B.
 


anonymous said:
I kinda believe in this post. Lundbeck reps may be good but they wouldn't know much, if anything, about bill to/send to purchasing accounts. They will need experienced account reps with infusion sales experience and B&B.
Click to expand...

They’ve actively been looking for something for their neurology team to sell since Northera will be going generic in 2021. They’re not looking to build another sales team, they wanted something that would fit with their current sales team
 






anonymous said:
I think all of these posts are just a guess. CP has a rep super negativity. There are so many ways this can go down. I'll wait to hear from the Alder people.
Click to expand...

Actually there aren’t that many ways for this to go.

If you have prior migraine or buy and bill, you might be kept over a poor performing Lundbeck psych rep.

Putting a field force of any more than 200 after this is just foolish.

As for the product, it is a niche opportunity at best for the clinics with an infusion suite. Biohaven will have an oral in about 18 months and three aggressive competitors with SC products will make this a near impossibility in the non specialist and PCP market.

Lundbeck overpaid and they are going to need to make it up somehow. High goals, high price, high pressure and high turnover.
 




B&B is not rocket science. Anyone can learn it. That’s why when the Alder mgmt was all, “Do you have buy and bill”? “How many years, how many products”? I knew they were clueless. If you have it, you have it. If you don’t, you can easily learn it!
 


anonymous said:
I think all of these posts are just a guess. CP has a rep super negativity. There are so many ways this can go down. I'll wait to hear from the Alder people.
Click to expand...

I’m confused why people are in such denial. Lundbeck has two sales teams capable of selling this. They were looking for a late stage drug for their current sales team. Alder doesn’t even have a sales team! Why do people who were interviewing with Alder (that never even got a written offer!) think they’re in the running to take a Lundbeck rep’s job?! Move on
 


IDK. Could Lundbeck keep Alder as a wholly owned subsidiary? Other companies have done it. Might offer financial advantages. If Lundbeck does keep the MAB in house, then yes, the drug is doomed. The Vantage article is crap from a drug standpoint. This drug is a winner, but only in the right hands. Alder could do it. Lundbeck cannot.
 


anonymous said:
I’m confused why people are in such denial. Lundbeck has two sales teams capable of selling this. They were looking for a late stage drug for their current sales team. Alder doesn’t even have a sales team! Why do people who were interviewing with Alder (that never even got a written offer!) think they’re in the running to take a Lundbeck rep’s job?! Move on[/QUOTE

I don’t think it’s about denial. Neither team can sell this drug. As for Alder, I like the little guys going against the big guys. The difference is Lundbeck is big pharma without the financial muscle. They can’t pay top talent, they have no equity. Alder hired top managers that understood the lay of the land and they in turn were in the process of hiring top talent to get it done.
Click to expand...
 


Current Alder staff here - about as far from “sales” as one may be.

The contrarians here neglect patient demand for epti, which is huge. Incentive pricing for clinicians is a foot in the door, but migraine suffers are going to be begging for this scrip. I wish Lundbeck sales staff all the best! Patients first. Selah.
 




I got a call and email basically saying you’ll be contacted “if” after the deal closes they want to move forward. In my book that is their way of saying sorry for wasting your time...but move along now.
 


anonymous said:
Actually there aren’t that many ways for this to go.

If you have prior migraine or buy and bill, you might be kept over a poor performing Lundbeck psych rep.

Putting a field force of any more than 200 after this is just foolish.

As for the product, it is a niche opportunity at best for the clinics with an infusion suite. Biohaven will have an oral in about 18 months and three aggressive competitors with SC products will make this a near impossibility in the non specialist and PCP market.

Lundbeck overpaid and they are going to need to make it up somehow. High goals, high price, high pressure and high turnover.
Click to expand...

Bohaven will have their oral migraine out within 6 months not 18. Sorry for your luck.
 


anonymous said:
Bohaven will have their oral migraine out within 6 months not 18. Sorry for your luck.
Click to expand...

Given that it hasn’t even filed yet, 6 months may be a bit on the optimistic side.

Either way, this is a classic case of Lundbeck BD doing a deal just to do a deal.

The commercial input was either non existent or ill informed.
 








anonymous said:
I got a call and email basically saying you’ll be contacted “if” after the deal closes they want to move forward. In my book that is their way of saying sorry for wasting your time...but move along now.
Click to expand...

There were comments about folks that got verbal offers last week and were expecting written ones. Did anyone get an offer for a field sales position? I have to say that I’ve been around for 25 years in our industry and I find it shady that Alder wasted so many people’s time prepping and flying to interviews only to say oops. It’s on hold. It’s not like one day they were putting together a sales force and they poof- the next day Lundbeck décides to drop
2 billion
 



Write your reply...
Top Bottom
Back
Quote